Female Hypoactive Sexual Desire Disorder Therapeutics Market Size And Share

  • Report Code : TIPRE00010487
  • Category : Life Sciences
  • No. of Pages : 150
Buy Now

Analyse des parts de marché et principaux résultats du traitement du trouble du désir sexuel hypoactif féminin d'ici 2025-2031

Buy Now

Female Hypoactive Sexual Desire Disorder Therapeutics Market Report Analysis

Female Hypoactive Sexual Desire Disorder Therapeutics Market

  • CAGR (2023 - 2031)
    XX%
  • Market Size 2023
    US$ XX million
  • Market Size 2031
    US$ XX Million

Report Coverage

  • Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
  • Key future trends
  • Detailed PEST/Porter’s Five Forces and SWOT analysis
  • Industry landscape and competition analysis & recent developments
  • Detailed company profiles
  • Global and regional market analysis covering key market trends, major players, regulations, and recent market developments

Key Players

  • Allergan plc
  • AMAG Pharmaceuticals, Inc.
  • Emotional Brain BV
  • Endoceutics, Inc.
  • GlaxoSmithKline Plc
  • Merck & Co., Inc.
  • Palatin Technologies Inc
  • Pivot Pharmaceuticals Inc
  • Sprout Pharmaceuticals, Inc.

Regional Overview

  • Amérique du Nord
  • Europe
  • Asie-Pacifique
  • Amérique du Sud et centrale
  • Moyen-Orient et Afrique

Market Segmentation

By Thérapie
  • testostérone
  • flibansérine
  • buspirone
  • bupropion
  • bremelanotide
  • thérapie cognitivo-comportementale
By Demande
  • hospitalisation
  • ambulatoire
By Géographie
  • Amérique du Nord
  • Europe
  • Asie-Pacifique
  • Amérique du Sud et Centrale